Press releases

All Press releases are available in Swedish.

Cyxone strengthens its market position through the acquisition of patent portfolio

Today, Cyxone announce that they will acquire the entire family of patents protecting the Company's main candidate T20K, from the Medical University of Vienna. The cost of € 100,930 includes VAT and corresponds to the costs of the patenting process.

The cyclotide based lead candidate was licensed in 2015, through the holding company Accequa, to technically verify performance before a full acquisition. In line with Cyxone's requirements, T20K has demonstrated significant beneficial qualities - such as low toxicity and a large interval between the effective dose and the dose that can cause toxic effects in animals - that form the basis of today's announcement.

"T20K has, to date, shown significant potential to become a competitive Multiple Sclerosis drug with minor side effects. It is therefore with great pleasure we announce the decision to obtain complete control over our lead candidate in line with our strategy. This acquisition establishes security for the company's overall development program for cyclotides and security for our shareholders", remarks Cyxone's CEO, Kjell G Stenberg.

Multiple sclerosis is a global disease, and the company has applied for patent protection of T20K in key markets. The patent portfolio includes a patent recently approved in the United States and several international patent applications, which are under review.

"This acquisition is important for strategic partnership negotiations that are planned to follow the completion of preclinical and Phase I clinical studies with T20K. Ownership of the patent rights will facilitate negotiations with potential buyers, strengthen the value of the company's technology and facilitate defense of the cyclotide technology from patent infringement by potential competitors " adds Cyxone's chairman, Bert Junno.

Cyxone intends to complete the transaction with the Medical University of Vienna in the first quarter of 2017.

2016-12-21

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: 070-716 80 09
E-mail: kjell.g.stenberg@cyxone.com
Adelgatan 21
221 22 Malmö
www.cyxone.com

This is information which Cyxone AB (publ) is required to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person for publication on December 19, 2016 at. 09:25 CET.

About Cyxone
Cyxone AB (publ) is a biopharmaceutical company developing drugs based on cyclotides, a class of natural plant proteins. Cyclotide technology has the potential to provide new drugs offering beneficial pharmacological effects for diseases that currently lack effective and safe treatments. The company is focusing on the development of T20K, a substance which inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxones Certified Adviser on Nasdaq First North is Erik Penser Bank.

February 16, 2018
Regulatory

Summary of the Year-end Report

Fourth Quarter (1 October to 31 December 2017)

  • Operating revenue KSEK 0 (21)
  • Income after financial items KSEK -3 231 (-1 301)
  • Earnings per share -0,18 (-0,10)
  • Cash and cash equivalents as of 31 December KSEK 33 357 (21 598)
  • Equity ratio as of 31 December 90,4 (96,9) %

Financial year (1 January to 31 December 2017)

  • Operating revenue KSEK 0 (21)
  • Income after financial items KSEK -8 824 (-4 162)
  • Earnings per share SEK -0,50 (-0,32)
Read more
January 31, 2018

In response to interest from drug companies, Cyxone is to review whether cyclotides are effective against inflammatory bowel disease (IBD). The study was planned by the Medical University of Vienna and is now underway.

Read more
December 11, 2017
Regulatory

Today, December 11, 2017, Cyxone AB (publ.) held an extraordinary general meeting. Below is an overview of the motions decided upon. All motions were taken with the necessary majority of votes.

Read more
November 23, 2017
Regulatory

Shareholders in Cyxone AB (publ.), 559020-5471, are hereby invited to an extraordinary general meeting at Setterwalls Advokatbyrå AB, Stortorget 23, in Malmö, on Monday, December 11, 2017 at 10:00AM.

Read more
November 23, 2017
Regulatory

As previously announced, Cyxone acquired Rabeximod from OxyPharma in June 2017. Rabeximod has undergone Phase 2 trials in patients with moderate to severe rheumatoid arthritis in which significant improvements in the condition's symptoms were discovered four weeks after the completion of the formal (12 week) trial period.

Read more
November 06, 2017
Regulatory

Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.

Read more
October 26, 2017
Regulatory

Summary

Period (July 1 to September 30, 2017)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1,518 (-1,235)
  • Earnings per share SEK -0,10 (-0,10) Cash and cash equivalents as of September 30 KSEK 25,662 (23,468)
  • Equity ratio as of September 30 95.2% (97.7%)

Period (January 1 to September 30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -5,593 (-2,860)
  • Earnings per share SEK -0,36 (-0,22)
Read more
October 26, 2017
Regulatory
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.
Read more
October 13, 2017
Regulatory

In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.

Read more
1
2
3